Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

Unraveling the Role of Adjuvanted Flu Vaccines for Older High-Risk Patients

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in to learn how routine vaccinations against the flu, especially with adjuvanted vaccines, could have a significant impact on preventing severe complications and deaths in older adult patients.

Please See

Important Safety Information

  • Sponsored by

  • Overview

    Influenza disproportionately affects adults 65 and older as a result of increased frequency of comorbidities and immunosenescence.1,2 It is also linked to neurologic, cardiovascular, and respiratory complications in high-risk groups, while potentially exacerbating underlying chronic medical conditions.1,2 So how can adjuvanted vaccines help patients who are affected? Dive in to learn more with Dr. Stephen Pelton, Professor of Pediatrics at Boston University Chobanian and Avedisian School of Medicine.

    References:

    1. Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA.
    2. Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023; 11(10):1525. https://doi.org/10.3390/vaccines11101525

    USA-FLUD-24-0039 08/24

  • FLUAD® (Influenza Vaccine, Adjuvanted)

    INDICATION AND IMPORTANT SAFETY INFORMATION

    INDICATION AND USAGE
    FLUAD is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in adults 65 years of age and older.

    This indication is approved under accelerated approval based on the immune response elicited by FLUAD. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    Do not administer FLUAD to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

    WARNINGS AND PRECAUTIONS
    If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza
    vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

    Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD.

    Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD. Procedures should be in place to avoid injury from fainting.

    The immune response to FLUAD in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

    Vaccination with FLUAD may not protect all vaccine recipients against influenza disease.

    ADVERSE REACTIONS

    The most common (≥10%) local and systemic adverse reactions in adults 65 years of age and older who received FLUAD were injection site pain (25%), injection site tenderness (21%), myalgia (15%), fatigue (13%) and headache (13%).

    Other adverse events may occur.

    To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

    Before administration, please see the full US Prescribing Information for FLUAD.

Schedule15 Oct 2024